Philadelphia, United States
Scout Bio, founded in 2016, is a pioneering player in the Biotechnology industry, strategically positioned within the Health Care and Health and Wellness sectors. The company's mission, encapsulated in their slogan, "Shaping the future of veterinary medicine through one-time therapies for major chronic pet health conditions," highlights its innovative approach. By building on the advancements in genetic medicine, Scout Bio aims to revolutionize the field of veterinary medicine with cutting-edge gene therapy technology.
Headquartered in the United States, the company is backed by a robust investor ecosystem, including Correlation Ventures, Greenspring Associates, Frazier Healthcare Partners, OrbiMed, RiverVest, Adage Capital Management, and Digitalis Ventures. Their most recent funding, a $33.00M Series B investment, occurred on October 19, 2021.
A notable development is their ongoing study targeting anemia in cats with chronic kidney disease (CKD), utilizing a single injection therapy with the potential to provide lifelong relief. This reflects Scout Bio's commitment to addressing unmet medical needs in pet healthcare, leveraging partnerships with esteemed institutions like the Gene Therapy Program at the University of Pennsylvania.
